Published in Medical Devices and Surgical Technology Week, October 17th, 2004
RTX is "a monoclonal antibody which targets CD20 and is approved for treatment of non-Hodgkin's lymphoma (NHL), with an approximate 50% overall response rate among NHL patients," according to scientists in the United States. "Accurate determination of RTX concentrations in patient plasmas is important for proper dosing of patients and for correlating RTX concentrations with clinical responses."
However, there is "currently no assay available for RTX which utilizes easily obtainable commercial reagents," noted P.V. Beum and colleagues at the University of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week